<p>Atherosclerosis is a progressive inflammatory disease that is characterized by the accumulation of lipids, infiltrated cells and fibrous elements in large arteries.</p><p>This thesis focuses on the molecular mechanisms behind foam cell formation and inflammation, two central processes in the development of atherosclerosis. More specific, we studied the effects of proinflammatory cytokines on CXCL16 expression and its role as scavenger receptor on macrophages and smooth muscle cells in atherogenesis. CXCL16 is defined as a chemokine and a scavenger receptor, regulating adhesion and chemoattraction of CXCR6 expressing cells and uptake of oxLDL. We show that the expression of CXCL16 and its receptor CXCR6 are more pronounced in human atherosclerotic lesions compared with non-atherosclerotic vessels. Increased expression of CXCL16 was also seen in atherosclerotic aortas of apoE-/- mice compared with aortas of non-atherosclerotic, age-matched C57BL/6 mice. In vitro, IFN gamma induced CXCL16 expression in primary human monocytes and smooth muscle cells which resulted in an increased uptake of oxLDL. Treatment of mice with IFN gamma also induced CXCL16 expression in atherosclerotic lesions. Thus, we have demonstrated a role for IFN gamma in foam cell formation through upregulation of CXCL16. The expression of CXCR6 was defined to the same regions as for CXCL16 in the lesion, indicating the presence of cells able to respond to CXCL16. Consequently, CXCL16 could serve as a molecular link between lipid metabolism and immune activity in atherosclerotic lesion.</p><p>CD137 belongs to the TNF family and mediates several important processes in inflammation. CD137 is involved in the activation of T cells, NK cells, B cells and monocytes and regulate cytokine production, proliferation and apoptosis in these cells. A limited number of studies have demonstrated CD137 expression on smooth muscle cells and endothelial cells. Our results show that CD137 mRNA is higher expressed in human atherosclerotic lesions compared with unaffected vessels. We found that endothelial cells express CD137 in atherosclerotic lesions and that cultured endothelial cells and smooth muscle cells express CD137 and CD137 ligand in vitro. CD137 was regulated differentially by proinflammatory cytokines (i.e. IFN gamma, TNF alpha, IL-1 beta) and bacterial lipopolysaccharide depending on cell type. Furthermore, we investigated the effects of CD137 signalling, demonstrating that binding of the CD137 ligand to its receptor increases proliferation and migration of smooth muscle cells.</p><p>In summary, this thesis has focused on the expression, regulation and role of CXCL16 and CD137, two genes that have not been described earlier in the concept of atherosclerosis. The findings demonstrate some of the molecular mechanisms involved in vascular inflammation and may increase our knowledge about the development of atherosclerosis.</p>

T cells, which constitute an essential arm in the adaptive immunity, complete their development in the thymus through a process called thymopoiesis. However, thymic involution can be induced by a couple of factors, which impairs T cell functions and is slow to recover. Therefore, understanding how thymopoiesis is regulated may lead effort to accelerate thymic recovery and improve immune functions in thymocyte-depleted patients. In this project, we identified scavenger receptor BI (SR-BI), a high density lipoprotein (HDL) receptor, as a novel modulator in thymopoiesis. In mice, absence of SR-BI causes a significant reduction in thymus size after puberty and a remarkable decrease in thymic output. Consequently, SR-BI-null mice show a narrowed naïve T cell pool in the periphery and blunted T cell responses, indicating that the impaired thymopoiesis due to SR-BI deficiency leads to compromised T cell homeostasis and functions. The impaired thymopoiesis of SR-BI-null mice is featured by a significant reduction in the percentage of earliest T progenitors (ETPs) but unchanged percentages of other thymocyte subtypes, suggesting that SR-BI deficiency causes a reduction in progenitor thymic entry. Further investigations reveal that SR-BI deficiency impairs thymopoiesis through affecting bone marrow progenitor thymic homing without influencing the lymphoid progenitor development in bone marrow. Importantly, SR-BI-null mice exhibit delayed thymic recovery after sublethal irradiation, indicating that SR-BI is also required for thymic regeneration. Using bone marrow transplantation models, we elucidate that it is non-hematopoietic rather than hematopoietic SR-BI deficiency that results in the defects in thymopoiesis. However, SR-BI deficiency-induced hypercholesterolemia is not responsible for the impaired thymopoiesis. Using adrenal transplantation models, we found that absence of adrenal SR-BI is responsible for the impaired thymopoiesis, as shown by that adrenalectomized mice transplanted with SR-BI-null adrenal gland display reduced thymus size, decreased percentage of ETPs and delayed thymic regeneration compared with those transplanted with wild-type adrenal. Altogether, results from this study elucidate a previously unrecognized role of SR-BI in thymopoiesis. We reveal that SR-BI expressed in adrenal gland is critical in maintaining normal T cell development and enhancing thymic regeneration, providing novel links between adrenal functions and T cell development.

Macrófagos (Mf) produzem PAF e PAF-R e eliminam partículas alteradas via CD36. Uptake de oxLDL requer associação CD36/PAF-R. Avaliamos isto na eferocitose. Bloqueio do PAF-R e de lipid rafts (LR) inibiu eferocitose. Esta induziu associação PAF-R/CD36 e destes com flotilina-1 (marca LR). Eferocitose induziu IL-10 e IL-12p40. Bloqueio do PAF-R inibiu mais IL-10 e inibição da COX-2 teve efeito similar, sugerindo que eferocitose depende da interação PAF-R/CD36 em LR e que isto induz prostanoides e perfil regulador. Mf adquirirem diferentes fenótipos. Estudamos a participação do PAF-R. Bloqueio do PAF-R antes dos estímulos (IFN-g/LPS, IL-4 ou IgG-SRBC/LPS) inibiu marcadores MCP-1, TNF-a, iNOS, receptor manose, arginase-1 e IL-10, mas não IL-12p40, sugerindo que PAF-R modula fenótipo de Mf. PAF e PAF-like são gerados por estressores oxidativos. Ativação do PAF-R induz imunossupressão sistêmica (IS). Mostramos que terapia fotodinâmica (PDT) in vitro gerou ligantes do PAF-R e in vivo inibiu reação de CHS em WT, mas não em PAF-R KO, sugerindo que PDT induz IS via PAF-R. / Macrophages (Mp) produce PAF and PAF-R and scavenge altered particles via CD36. oxLDL uptake requires association CD36/PAF-R. We analyzed that on efferocytosis. PAF-R and lipid rafts (LR) blockage inhibited efferocytosis. Efferocytosis induced association CD36/PAF-R and both with LR marker protein, and induced IL-10 and IL-12p40. PAF-R and COX-2 blockage inhibited more IL-10, suggesting that efferocytosis depends on PAF-R/CD36 interaction in LR and that this induces prostanoids and regulatory profile. Mp acquire different phenotypes. PAF-R participation in that was analyzed. PAF-R blockage before stimuli (IFN-g/LPS, IL-4 or IgG-SRBC/LPS) inhibited markers MCP-1, TNF-a, iNOS, mannose receptor, arginase-1 and IL-10, but not IL-12p40, suggesting that PAF-R modulates Mp phenotype. PAF and PAF-like are generated by oxidative stressors. PAF-R activation induces systemic immunosuppression (SI). We showed that photodynamic therapy (PDT) in vitro generated PAF-R ligands and in vivo inhibited CHS reaction in WT, but not PAF-R KO, suggesting that PDT induces SI via PAF-R.

Ziel dieser Dissertationsschrift war es, die Effekte des oxidativen Stresses in Form von oxLDL auf die Expression der atherogenen Scavenger-Rezeptoren CD36, SR-BI, des Transkriptionsfaktors PPARγ und pro-inflammatorischer Zytokine zu untersuchen. Die durchgeführten Untersuchungen beruhen auf der Annahme, dass modifizierte LDL durch Induktion der genannten Scavenger-Rezeptoren und nachfolgende unregulierte Aufnahme in Makrophagen mit Bildung von Schaumzellen entscheidend zur Entwicklung einer Atherosklerose beitragen. Dabei scheint vor allem die im Rahmen des oxidativen Stresses auftretende oxidative Modifizierung der LDL eine Rolle zu spielen. Oxidativem Stress wird in der Pathogenese vieler Krankheiten eine Bedeutung zugesprochen, deren pathobiochemische Grundlagen jedoch noch nicht vollständig geklärt sind und zu deren Erforschung diese Dissertation beitragen sollte. Im ersten Versuchsteil wurden deshalb in vitro – Versuche zu Expressionsraten oben genannter Rezeptoren durchgeführt. Dabei wurden Hypochlorit-oxidierte LDL genutzt, denen im Gegensatz zu den in vielen Versuchen verwendeten Kupfer-oxidierten LDL auch in vivo eine pathophysiologische Relevanz zukommt. Desweiteren ist bekannt, dass Diabetiker neben einem hohen Risiko an Atherosklerose zu erkranken, auch laborchemisch erhöhte Marker des oxidativen Stresses zeigen, inklusive einer gesteigerten Menge an zirkulierenden oxLDL. Im zweiten Versuchsteil wurde deshalb ex vivo untersucht, inwiefern LDL, gewonnen von Patienten im prädiabetischen Stadium der gestörten Glukosetoleranz, ähnliche Auswirkungen auf die Expression von Scavenger-Rezeptoren zeigen, wie in den mit Hypochlorit-oxidierten LDL durchgeführten in vitro - Untersuchungen beobachtet werden konnte. Es zeigte sich, dass CD36, der für die Aufnahme von oxidativ modifizierten LDL als der bedeutendste Rezeptor gilt, durch Hypochlorit-oxidierte LDL stark induziert wird. Zusammengenommen mit der ebenfalls beobachteten Heraufregulation des Transkriptionsfaktors PPARγ, sowie der signifikanten Korrelation beider Gene kann damit für Hypochlorit-oxidierte LDL eine atherogene Wirkung nachgewiesen werden. Die Ergebnisse bestätigen zudem die von Nagy und Tontonoz zuerst beschriebene Feed-Forward-Schleife, bei der oxidative LDL über Induktion und Aktivierung von PPARγ die Expression von CD36 erhöhen, mit nachfolgender unregulierter Aufnahme von Cholesterolestern in Makrophagen und subsequenter Bildung von Schaumzellen. Die Versuche zeigen zudem, dass der Scavenger-Rezeptor SR-BI, obwohl strukturell stark mit CD36 verwandt, eine differentielle Regulation aufweist und durch oxidativ modifizierte LDL signifikant supprimiert wird. Eine Induktion durch PPARγ, wie sie eindrucksvoll bei CD36 beobachtet werden kann, ist für SR-BI in den in vitro - Versuchen nicht vorhanden. Mit der in vielen Studien SR-BI, jedoch nicht CD36 zugesprochenen Funktion als Vermittler des HDL-Membranstransports gehen damit auch unterschiedliche Regulationsmechanismen einher. Die Ausschüttung pro-inflammatorischer Zytokine in murinen Makrophagen wurde durch Hypochlorit-oxidierte LDL im Vergleich mit nativen LDL signifikant vermindert, eine Assoziation mit dem Transkriptionsfaktor PPARγ konnte nicht gefunden werden. Die für die ex vivo - Versuche untersuchten Gruppen der insgesamt 40 Probanden mit gestörter und normaler Glukosetoleranz wiesen, mit Ausnahme eines pathologischen Glukosetoleranztests für IGT-Patienten, in der klinischen Untersuchung, beim Vergleich der Laborparameter, ebenso wie in der Zusammensetzung der LDL keine signifikanten Unterschiede auf. Dennoch fand sich eine signifikante Erhöhung der CD36-Expression in Makrophagen schon nach einstündiger Inkubation mit LDL aus IGT-Patienten im Vergleich zu LDL von Probanden mit normaler Glukosetoleranz. Für die Expressionsraten von SR-BI, PPARγ und die Zytokinausschüttung konnten nur marginale Unterschiede zwischen den Probandengruppen erfasst werden. Auch in den ex vivo – Untersuchungen wiesen eine insignifikante PPARγ - Erhöhung und eine positive Korrelation zwischen PPARγ und CD36 auf die Existenz und Aktivierung der beschriebenen atherogenen Feed-Forward-Schleife auch in IGT-Patienten hin. Zusammenfassend unterstreicht diese Dissertationsschrift die Bedeutung des oxidativen Stresses in der Entwicklung der Atherosklerose, indem erstmals auch für das pathophysiologisch relevante Hypochlorit-oxidierte LDL eine deutliche Expressionssteigerung des Scavenger-Rezeptors CD36 und des Transkriptionsfaktor PPARγ nachgewiesen werden konnte. Zudem zeigen die Experimente, dass bereits bei Patienten im Vorstadium des Diabetes mellitus Typ 2 funktionelle Veränderungen der LDL eingetreten sind, die zu einer verstärkten Atherosklerose führen können und die denen gleichen, die durch künstlich oxidierte LDL ausgelöst werden. Die Versuche liefern damit eine mögliche Erklärung für den bereits epidemiologisch nachgewiesenen Zusammenhang zwischen oxidativem Stress, Atherosklerose und Diabetes mellitus.

Atherosclerosis is a progressive inflammatory disease that is characterized by the accumulation of lipids, infiltrated cells and fibrous elements in large arteries. This thesis focuses on the molecular mechanisms behind foam cell formation and inflammation, two central processes in the development of atherosclerosis. More specific, we studied the effects of proinflammatory cytokines on CXCL16 expression and its role as scavenger receptor on macrophages and smooth muscle cells in atherogenesis. CXCL16 is defined as a chemokine and a scavenger receptor, regulating adhesion and chemoattraction of CXCR6 expressing cells and uptake of oxLDL. We show that the expression of CXCL16 and its receptor CXCR6 are more pronounced in human atherosclerotic lesions compared with non-atherosclerotic vessels. Increased expression of CXCL16 was also seen in atherosclerotic aortas of apoE-/- mice compared with aortas of non-atherosclerotic, age-matched C57BL/6 mice. In vitro, IFN gamma induced CXCL16 expression in primary human monocytes and smooth muscle cells which resulted in an increased uptake of oxLDL. Treatment of mice with IFN gamma also induced CXCL16 expression in atherosclerotic lesions. Thus, we have demonstrated a role for IFN gamma in foam cell formation through upregulation of CXCL16. The expression of CXCR6 was defined to the same regions as for CXCL16 in the lesion, indicating the presence of cells able to respond to CXCL16. Consequently, CXCL16 could serve as a molecular link between lipid metabolism and immune activity in atherosclerotic lesion. CD137 belongs to the TNF family and mediates several important processes in inflammation. CD137 is involved in the activation of T cells, NK cells, B cells and monocytes and regulate cytokine production, proliferation and apoptosis in these cells. A limited number of studies have demonstrated CD137 expression on smooth muscle cells and endothelial cells. Our results show that CD137 mRNA is higher expressed in human atherosclerotic lesions compared with unaffected vessels. We found that endothelial cells express CD137 in atherosclerotic lesions and that cultured endothelial cells and smooth muscle cells express CD137 and CD137 ligand in vitro. CD137 was regulated differentially by proinflammatory cytokines (i.e. IFN gamma, TNF alpha, IL-1 beta) and bacterial lipopolysaccharide depending on cell type. Furthermore, we investigated the effects of CD137 signalling, demonstrating that binding of the CD137 ligand to its receptor increases proliferation and migration of smooth muscle cells. In summary, this thesis has focused on the expression, regulation and role of CXCL16 and CD137, two genes that have not been described earlier in the concept of atherosclerosis. The findings demonstrate some of the molecular mechanisms involved in vascular inflammation and may increase our knowledge about the development of atherosclerosis.

Ziel dieser Dissertationsschrift war es, die Effekte des oxidativen Stresses in Form von oxLDL auf die Expression der atherogenen Scavenger-Rezeptoren CD36, SR-BI, des Transkriptionsfaktors PPARγ und pro-inflammatorischer Zytokine zu untersuchen. Die durchgeführten Untersuchungen beruhen auf der Annahme, dass modifizierte LDL durch Induktion der genannten Scavenger-Rezeptoren und nachfolgende unregulierte Aufnahme in Makrophagen mit Bildung von Schaumzellen entscheidend zur Entwicklung einer Atherosklerose beitragen. Dabei scheint vor allem die im Rahmen des oxidativen Stresses auftretende oxidative Modifizierung der LDL eine Rolle zu spielen. Oxidativem Stress wird in der Pathogenese vieler Krankheiten eine Bedeutung zugesprochen, deren pathobiochemische Grundlagen jedoch noch nicht vollständig geklärt sind und zu deren Erforschung diese Dissertation beitragen sollte. Im ersten Versuchsteil wurden deshalb in vitro – Versuche zu Expressionsraten oben genannter Rezeptoren durchgeführt. Dabei wurden Hypochlorit-oxidierte LDL genutzt, denen im Gegensatz zu den in vielen Versuchen verwendeten Kupfer-oxidierten LDL auch in vivo eine pathophysiologische Relevanz zukommt. Desweiteren ist bekannt, dass Diabetiker neben einem hohen Risiko an Atherosklerose zu erkranken, auch laborchemisch erhöhte Marker des oxidativen Stresses zeigen, inklusive einer gesteigerten Menge an zirkulierenden oxLDL. Im zweiten Versuchsteil wurde deshalb ex vivo untersucht, inwiefern LDL, gewonnen von Patienten im prädiabetischen Stadium der gestörten Glukosetoleranz, ähnliche Auswirkungen auf die Expression von Scavenger-Rezeptoren zeigen, wie in den mit Hypochlorit-oxidierten LDL durchgeführten in vitro - Untersuchungen beobachtet werden konnte. Es zeigte sich, dass CD36, der für die Aufnahme von oxidativ modifizierten LDL als der bedeutendste Rezeptor gilt, durch Hypochlorit-oxidierte LDL stark induziert wird. Zusammengenommen mit der ebenfalls beobachteten Heraufregulation des Transkriptionsfaktors PPARγ, sowie der signifikanten Korrelation beider Gene kann damit für Hypochlorit-oxidierte LDL eine atherogene Wirkung nachgewiesen werden. Die Ergebnisse bestätigen zudem die von Nagy und Tontonoz zuerst beschriebene Feed-Forward-Schleife, bei der oxidative LDL über Induktion und Aktivierung von PPARγ die Expression von CD36 erhöhen, mit nachfolgender unregulierter Aufnahme von Cholesterolestern in Makrophagen und subsequenter Bildung von Schaumzellen. Die Versuche zeigen zudem, dass der Scavenger-Rezeptor SR-BI, obwohl strukturell stark mit CD36 verwandt, eine differentielle Regulation aufweist und durch oxidativ modifizierte LDL signifikant supprimiert wird. Eine Induktion durch PPARγ, wie sie eindrucksvoll bei CD36 beobachtet werden kann, ist für SR-BI in den in vitro - Versuchen nicht vorhanden. Mit der in vielen Studien SR-BI, jedoch nicht CD36 zugesprochenen Funktion als Vermittler des HDL-Membranstransports gehen damit auch unterschiedliche Regulationsmechanismen einher. Die Ausschüttung pro-inflammatorischer Zytokine in murinen Makrophagen wurde durch Hypochlorit-oxidierte LDL im Vergleich mit nativen LDL signifikant vermindert, eine Assoziation mit dem Transkriptionsfaktor PPARγ konnte nicht gefunden werden. Die für die ex vivo - Versuche untersuchten Gruppen der insgesamt 40 Probanden mit gestörter und normaler Glukosetoleranz wiesen, mit Ausnahme eines pathologischen Glukosetoleranztests für IGT-Patienten, in der klinischen Untersuchung, beim Vergleich der Laborparameter, ebenso wie in der Zusammensetzung der LDL keine signifikanten Unterschiede auf. Dennoch fand sich eine signifikante Erhöhung der CD36-Expression in Makrophagen schon nach einstündiger Inkubation mit LDL aus IGT-Patienten im Vergleich zu LDL von Probanden mit normaler Glukosetoleranz. Für die Expressionsraten von SR-BI, PPARγ und die Zytokinausschüttung konnten nur marginale Unterschiede zwischen den Probandengruppen erfasst werden. Auch in den ex vivo – Untersuchungen wiesen eine insignifikante PPARγ - Erhöhung und eine positive Korrelation zwischen PPARγ und CD36 auf die Existenz und Aktivierung der beschriebenen atherogenen Feed-Forward-Schleife auch in IGT-Patienten hin. Zusammenfassend unterstreicht diese Dissertationsschrift die Bedeutung des oxidativen Stresses in der Entwicklung der Atherosklerose, indem erstmals auch für das pathophysiologisch relevante Hypochlorit-oxidierte LDL eine deutliche Expressionssteigerung des Scavenger-Rezeptors CD36 und des Transkriptionsfaktor PPARγ nachgewiesen werden konnte. Zudem zeigen die Experimente, dass bereits bei Patienten im Vorstadium des Diabetes mellitus Typ 2 funktionelle Veränderungen der LDL eingetreten sind, die zu einer verstärkten Atherosklerose führen können und die denen gleichen, die durch künstlich oxidierte LDL ausgelöst werden. Die Versuche liefern damit eine mögliche Erklärung für den bereits epidemiologisch nachgewiesenen Zusammenhang zwischen oxidativem Stress, Atherosklerose und Diabetes mellitus.

O receptor scavenger classe B tipo I (SR-BI) media a captação seletiva do colesterol da lipoproteina de alta densidade (HDL) e participa no effluxo do colesterol livre para aceptores lipoprotéicos. A HDL tem um importante rol aterogênico associado com sua participação no transporte reverso do colesterol. Polimorfismos no gene que codifica para o SR-BI (SCARB1) foram relacionados com alterações do perfil lipídico sérico e outros fatores de risco associados com doença cardiovascular. As estatinas são inibidores da síntese do colesterol utilizados no tratamento da dislipidemia. Vários polimorfismos em genes envolvidos no metabolismo intermediario de lipideos foram relacionados com diferenças na resposta a hipolipemiantes. Com a finalidade de avaliar o efeito de polimorfismos do SCARB1 sobre o perfil lipídico sérico, expressão gênica e a resposta a estatinas, foram selecionados 185 indivíduos normolipidêmicos (NL) e 147 pacientes hipercolesterolêmicos (HC). Os pacientes HC foram tratados com atorvastatina (10 mg/dia/4 semanas). DNA e RNA foram extraídos de amostras de sangue periférico. Os polimorfismos de nucleotídeo único (SNP) G4A, In5C>T e Ex8C>T foram detectados por PCR-RFLP. A expressão de RNAm do SCARB1 em células mononucleares de sangue periférico (CMSP) foi analisada por PCR em tempo real usando o gene da Ubiquitina c (UBC) como referência endógena. Nos indivíduos HC, as freqüências dos alelos raros G4A (12%), In5C>T (7%) e Ex8C>T (40%), no grupo HC, foram similares às encontradas no grupo NL (4A: 15%, In5T: 7%, e Ex8T: 35%, p>0,05). O alelo SCARB1 4A (genótipos GA + AA) foi associado com valores diminuídos de apoAI no grupo NL. O alelo In5T foi associado com maior concentração LDL-C sérico (p=0,029), em NL, e com apoB e razão apoB/apoAI elevadas (p>0,05) no grupo HC. O SNP SCARB1 Ex8C>T não foi relacionado com o perfil lipídico sérico basal, embora os portadores do genótipo Ex8CC foram associados com resposta reduzida ao tratamento com atorvastatina mostrando menor variação de colesterol total, LDL-C, apoB e razão apoB/apoAI. O SNP Ex8C>T foi associado com maior probabilidade (OR=3,1; 95% IC: 1,00-9,5; p=0,044) de ter uma resposta à atorvastatina diminuída. Os SNPs SCARB1 In5C>T e Ex8C>T estão em desequilíbrio de ligação. O haplótipo G1C5C8/G1T5C8 foi associado com concentrações basais elevadas de triglicérides e VLDL-C em NL e diminuídas de HDL-C e apoAI em HC. Os haplótipos G1C5C8/A1C5C8 e C5C8/C5C8 tiveram variação diminuída da apoB quando comparados com os outros haplótipos, G1C5C8/A1C5C8 e o diplótipo C5C8/C5C8 também apresentou uma variação reduzida da razão apoB/apoAI. Os SNPs G4A e In5C>T estão associados com diminuição da expressão gênica do SCARB1 em NL. O tratamento com atorvastatina não modifica a expressão de RNAm do SCARB1 em CMSP nos HC. Esses resultados são sugestivos de que os polimorfismos no SCARB1 estão associados com valores basais do perfil lipídico sérico e de expressão de RNAm do SCARB1, assim como de resposta à atorvastatina. / The scavenger receptor class B type I (SR-BI) mediates the selective uptake of the high density lipoprotein (HDL) cholesterol and it participates in the free cholesterol efflux to lipoprotein acceptors. HDL has an important antiatherogenic role associated with important activity in the cholesterol reverse transport. Polymorphisms in the SR-BI gene (SCARB1) have been related to variations on plasma lipoprotein profile and other risk factors for cardiovascular disease. Statins are potent inhibitors of cholesterol synthesis prescribed for treatment of the dislipidemia. Several polymorphisms in genes involved in intermediary metabolism of lipids have been related to differences in response to lowering-cholesterol drugs. In order to evaluate the effect of SCARB1 polymorphisms on serum lipids, gene expression and lipid-lowering response to atorvastatin, 185 normolipidemic (NL) and 147 hypercholesterolemic (HC) individuals were selected. HC individuals were treated with atorvastatin (10 mg/day/4 weeks). DNA and RNA were extracted from peripheric blood mononuclear cells (PBMC). SCARB1 mRNA expression was analyzed by real time PCR using ubiquitin c gene (UBC) as endogenous reference. The frequencies of the rare alleles in HC group (G4A: 12%; In5C>T: 7%, and ExC>T: 39%) were similar to those found in NL individuals (4A: 15%, In5T: 7%, and Ex8T: 35%, p>0.05). The SCARB1 4A allele (GA+AA genotypes) was associated with lower apoAI concentration in NL. The In5T allele was associated with higher serum LDL-C (p=0,029) in NL individuals, and with higher apoB and apoB/apoAI ratio (p>0,05) in HC group. SCARB1 Ex8C>T SNP was not related to serum lipids profile, however Ex8CC genotype carriers had lower variation of total cholesterol, LDL-C, apoB and apoB/apoAI ratio in response to atorvastatin. SCARB1 Ex8C>T was associated with higher chance to have a lower atorvastatin response (OR=3.1, 95% CI: 1.00-9.5; p=0.044). SCARB1 In5C>T and ExC>T were in linkage disequilibrium. G1C5C8/G1T5C8 SCARB1 haplotype was associated with higher level of triglycerides and VLDL-C in NL and lower HDL-C and apoAI levels in HC individuals. G1C5C8/A1C5C8 haplotype and C5C8/C5C8 diplotype had lower variations on apoB than the other haplotypes, and G1C5C8/A1C5C8 had also lower variation on apoB/apoAI ratio. G4A and In5C>T SNPs are associated with lower SCARB1 mRNA expression in PBMC of NL individuals. Atorvastatin therapy did not modify the expression level of the SCARB1 transcript in HC. Our results suggest that SCARB1 polymorphisms are associated with basal serum lipids profile, mRNA SCARB1 expression and atorvastatin response.

O receptor scavenger classe B tipo I (SR-BI) media a captação seletiva do colesterol da lipoproteina de alta densidade (HDL) e participa no effluxo do colesterol livre para aceptores lipoprotéicos. A HDL tem um importante rol aterogênico associado com sua participação no transporte reverso do colesterol. Polimorfismos no gene que codifica para o SR-BI (SCARB1) foram relacionados com alterações do perfil lipídico sérico e outros fatores de risco associados com doença cardiovascular. As estatinas são inibidores da síntese do colesterol utilizados no tratamento da dislipidemia. Vários polimorfismos em genes envolvidos no metabolismo intermediario de lipideos foram relacionados com diferenças na resposta a hipolipemiantes. Com a finalidade de avaliar o efeito de polimorfismos do SCARB1 sobre o perfil lipídico sérico, expressão gênica e a resposta a estatinas, foram selecionados 185 indivíduos normolipidêmicos (NL) e 147 pacientes hipercolesterolêmicos (HC). Os pacientes HC foram tratados com atorvastatina (10 mg/dia/4 semanas). DNA e RNA foram extraídos de amostras de sangue periférico. Os polimorfismos de nucleotídeo único (SNP) G4A, In5C>T e Ex8C>T foram detectados por PCR-RFLP. A expressão de RNAm do SCARB1 em células mononucleares de sangue periférico (CMSP) foi analisada por PCR em tempo real usando o gene da Ubiquitina c (UBC) como referência endógena. Nos indivíduos HC, as freqüências dos alelos raros G4A (12%), In5C>T (7%) e Ex8C>T (40%), no grupo HC, foram similares às encontradas no grupo NL (4A: 15%, In5T: 7%, e Ex8T: 35%, p>0,05). O alelo SCARB1 4A (genótipos GA + AA) foi associado com valores diminuídos de apoAI no grupo NL. O alelo In5T foi associado com maior concentração LDL-C sérico (p=0,029), em NL, e com apoB e razão apoB/apoAI elevadas (p>0,05) no grupo HC. O SNP SCARB1 Ex8C>T não foi relacionado com o perfil lipídico sérico basal, embora os portadores do genótipo Ex8CC foram associados com resposta reduzida ao tratamento com atorvastatina mostrando menor variação de colesterol total, LDL-C, apoB e razão apoB/apoAI. O SNP Ex8C>T foi associado com maior probabilidade (OR=3,1; 95% IC: 1,00-9,5; p=0,044) de ter uma resposta à atorvastatina diminuída. Os SNPs SCARB1 In5C>T e Ex8C>T estão em desequilíbrio de ligação. O haplótipo G1C5C8/G1T5C8 foi associado com concentrações basais elevadas de triglicérides e VLDL-C em NL e diminuídas de HDL-C e apoAI em HC. Os haplótipos G1C5C8/A1C5C8 e C5C8/C5C8 tiveram variação diminuída da apoB quando comparados com os outros haplótipos, G1C5C8/A1C5C8 e o diplótipo C5C8/C5C8 também apresentou uma variação reduzida da razão apoB/apoAI. Os SNPs G4A e In5C>T estão associados com diminuição da expressão gênica do SCARB1 em NL. O tratamento com atorvastatina não modifica a expressão de RNAm do SCARB1 em CMSP nos HC. Esses resultados são sugestivos de que os polimorfismos no SCARB1 estão associados com valores basais do perfil lipídico sérico e de expressão de RNAm do SCARB1, assim como de resposta à atorvastatina. / The scavenger receptor class B type I (SR-BI) mediates the selective uptake of the high density lipoprotein (HDL) cholesterol and it participates in the free cholesterol efflux to lipoprotein acceptors. HDL has an important antiatherogenic role associated with important activity in the cholesterol reverse transport. Polymorphisms in the SR-BI gene (SCARB1) have been related to variations on plasma lipoprotein profile and other risk factors for cardiovascular disease. Statins are potent inhibitors of cholesterol synthesis prescribed for treatment of the dislipidemia. Several polymorphisms in genes involved in intermediary metabolism of lipids have been related to differences in response to lowering-cholesterol drugs. In order to evaluate the effect of SCARB1 polymorphisms on serum lipids, gene expression and lipid-lowering response to atorvastatin, 185 normolipidemic (NL) and 147 hypercholesterolemic (HC) individuals were selected. HC individuals were treated with atorvastatin (10 mg/day/4 weeks). DNA and RNA were extracted from peripheric blood mononuclear cells (PBMC). SCARB1 mRNA expression was analyzed by real time PCR using ubiquitin c gene (UBC) as endogenous reference. The frequencies of the rare alleles in HC group (G4A: 12%; In5C>T: 7%, and ExC>T: 39%) were similar to those found in NL individuals (4A: 15%, In5T: 7%, and Ex8T: 35%, p>0.05). The SCARB1 4A allele (GA+AA genotypes) was associated with lower apoAI concentration in NL. The In5T allele was associated with higher serum LDL-C (p=0,029) in NL individuals, and with higher apoB and apoB/apoAI ratio (p>0,05) in HC group. SCARB1 Ex8C>T SNP was not related to serum lipids profile, however Ex8CC genotype carriers had lower variation of total cholesterol, LDL-C, apoB and apoB/apoAI ratio in response to atorvastatin. SCARB1 Ex8C>T was associated with higher chance to have a lower atorvastatin response (OR=3.1, 95% CI: 1.00-9.5; p=0.044). SCARB1 In5C>T and ExC>T were in linkage disequilibrium. G1C5C8/G1T5C8 SCARB1 haplotype was associated with higher level of triglycerides and VLDL-C in NL and lower HDL-C and apoAI levels in HC individuals. G1C5C8/A1C5C8 haplotype and C5C8/C5C8 diplotype had lower variations on apoB than the other haplotypes, and G1C5C8/A1C5C8 had also lower variation on apoB/apoAI ratio. G4A and In5C>T SNPs are associated with lower SCARB1 mRNA expression in PBMC of NL individuals. Atorvastatin therapy did not modify the expression level of the SCARB1 transcript in HC. Our results suggest that SCARB1 polymorphisms are associated with basal serum lipids profile, mRNA SCARB1 expression and atorvastatin response.